These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34511184)

  • 21. Vadadustat, a HIF Prolyl Hydroxylase Inhibitor, Improves Immunomodulatory Properties of Human Mesenchymal Stromal Cells.
    Zielniok K; Burdzinska A; Kaleta B; Zagozdzon R; Paczek L
    Cells; 2020 Nov; 9(11):. PubMed ID: 33139632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics.
    Chertow GM; Pergola PE; Agarwal R; Block GA; Farag YMK; Jardine AG; Koury MJ; Luo W; Khawaja Z; Lewis EF; Matsushita K; McCullough PA; Parfrey PS; Wittes J; Walters KA; Tseng C; Lin T; Sarnak MJ; Vargo DL; Winkelmayer WC; Eckardt KU
    Am Heart J; 2021 May; 235():1-11. PubMed ID: 33129989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Hypoxia-inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat (FG-4592) and Warfarin in Healthy Volunteers: A Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction Study.
    Groenendaal-van de Meent D; den Adel M; Rijnders S; Krebs-Brown A; Kerbusch V; Golor G; Schaddelee M
    Clin Ther; 2016 Apr; 38(4):918-28. PubMed ID: 26947173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
    Chen H; Cheng Q; Wang J; Zhao X; Zhu S
    J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and Efficacy of Vadadustat Once Daily and Three Times Weekly in Patients With Dialysis-Dependent CKD With Anemia.
    Kooienga L; Burke S; Kathresal A; Luo W; Yang Z; Zhang Z; Zwiech R; Hernandez GT
    Kidney360; 2024 Nov; 5(11):1652-1661. PubMed ID: 39231617
    [No Abstract]   [Full Text] [Related]  

  • 26. Novel roles of HIF-PHIs in chronic kidney disease: the link between iron metabolism, kidney function, and FGF23.
    Ikeda Y
    Kidney Int; 2021 Jul; 100(1):14-16. PubMed ID: 34154707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
    Provenzano R; Tumlin J; Zabaneh R; Chou J; Hemmerich S; Neff TB; Yu KP
    J Clin Pharmacol; 2020 Nov; 60(11):1432-1440. PubMed ID: 32603526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non-Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO
    Winkelmayer WC; Arnold S; Burke SK; Chertow GM; Eckardt KU; Jardine AG; Lewis EF; Luo W; Matsushita K; McCullough PA; Minga T; Parfrey PS
    Kidney Med; 2023 Jul; 5(7):100666. PubMed ID: 37427293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the effect of lanthanum carbonate hydrate on the pharmacokinetics of roxadustat in non-elderly healthy adult male subjects.
    Shibata T; Nomura Y; Takada A; Aoki S; Katashima M; Murakami H
    J Clin Pharm Ther; 2018 Oct; 43(5):633-639. PubMed ID: 29981285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Vadadustat for Anemia in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
    Xiong L; Zhang H; Guo Y; Song Y; Tao Y
    Front Pharmacol; 2021; 12():795214. PubMed ID: 35115942
    [No Abstract]   [Full Text] [Related]  

  • 31. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials.
    Eckardt KU; Agarwal R; Farag YM; Jardine AG; Khawaja Z; Koury MJ; Luo W; Matsushita K; McCullough PA; Parfrey P; Ross G; Sarnak MJ; Vargo D; Winkelmayer WC; Chertow GM
    Nephrol Dial Transplant; 2021 Nov; 36(11):2039-2048. PubMed ID: 33188693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects.
    Chong E; Kalia V; Willsie S; Winkle P
    J Nephrol; 2014 Dec; 27(6):659-66. PubMed ID: 24699894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of the Phosphate Binders Sevelamer Carbonate and Calcium Acetate on the Pharmacokinetics of Roxadustat After Concomitant or Time-separated Administration in Healthy Individuals.
    Groenendaal-van de Meent D; Kerbusch V; Barroso-Fernandez B; den Adel M; van Dijk J; Golor G; Schaddelee M
    Clin Ther; 2021 Jun; 43(6):1079-1091. PubMed ID: 33962762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
    Groenendaal-van de Meent D; Kerbusch V; Kaspera R; Barroso-Fernandez B; Galletti P; Klein GK; den Adel M
    Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):141-153. PubMed ID: 33165773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
    Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
    Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolyl-hydroxylase inhibitors reconstitute tumor blood vessels in mice.
    Nishide S; Uchida J; Matsunaga S; Tokudome K; Yamaguchi T; Kabei K; Moriya T; Miura K; Nakatani T; Tomita S
    J Pharmacol Sci; 2020 Jun; 143(2):122-126. PubMed ID: 32199747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of oral iron and calcium supplement on the pharmacokinetics and pharmacodynamics of molidustat: an oral HIF-PH inhibitor for the treatment of renal anaemia.
    Lentini S; Kaiser A; Kapsa S; Matsuno K; van der Mey D
    Eur J Clin Pharmacol; 2020 Feb; 76(2):185-197. PubMed ID: 31919558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
    Gupta N; Wish JB
    Am J Kidney Dis; 2017 Jun; 69(6):815-826. PubMed ID: 28242135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
    Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
    Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.